The decision by Swiss drugmaker Lonza to move cell-therapy work out of U.S. facility that was hit by an FDA warning letter last year will cost the plant about 125 jobs.
The CDMO recently said that it would concentrate its gene and cell therapy work at “centers of excellence.” Its sites in Pearland, Texas, and Geleen/Maastricht in the Netherlands will handle process and analytical development, as well as clinical and commercial supply, while sites in Portsmouth, New Hampshire and Singapore will do clinical and commercial manufacturing sites.
As a result, cell therapy work is being moved out of its site in Walkersville, Maryland, which was cited by the FDA last year. The Maryland site will concentrate on its bioscience solutions work providing custom and off-the-shelf media solutions.
John Mosack, senior site director for Lonza, told the Frederick News-Post that the move will affect about 125 of the 550 jobs at the site, but that the company hopes to keep some of those employees on as it expands its other work.
It already anticipated hiring nearly 60 employees this year. The company also is looking to see if some of those losing jobs might transfer to other Lonza sites.
The warning letter was issued last year after Lonza halted some production because of sterility problems with a cell therapy product it was producing for a client. Lonza first learned about the issue after “product end-user notified the FDA of the issue,” Lonza spokeswoman Constance Ward said at the time. The FDA warning letter uncovered issues that included with validation and aseptic process simulations.
Lonza some years back ran into FDA concerns about its biologics operations at an API plant it had in Hopkinton, Massachusetts, which was cited in 2011 for a plethora of problems. The action created supply problems for a drug it manufactured there for French drugmaker Ipsen.
After struggling to get issues resolved, Lonza simply closed the plant, eliminated 250 jobs, and concentrated its biologics work at its extensive site in Visp, Switzerland.
By Eric Palmer
Source: Fierce Pharma
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.